Intercell
{{Short description|Defunct biotechnology company in Austria}}
{{Infobox company
| name = Intercell AG
| logo = Intercell.svg
| logo_size = 120px
| type = Aktiengesellschaft
| traded_as = WBAG: ICLL
OTCQX: INRLY
| foundation = 1998
| founder =
| location_city = Vienna
| location_country = Austria
| locations =
| area_served =
| key_people = Thomas Lingelbach (CEO), Michel Gréco (Chairman of the supervisory board)
| industry = Biotechnology
| fate = Merged with Vivalis SA
| successor = Valneva SE
| defunct = {{End date|2013}}
| products = Development of vaccines
| services =
| operating_income = {{loss}} (€251.2 million) (2010)
| net_income = {{loss}} (€255.2 million) (2010)
| assets = €225.2 million (end 2010)
| equity = €121.1 million (end 2010)
| num_employees = 410 (average, 2010)
| divisions =
| subsid =
| homepage = {{URL|http://www.intercell.com/}}
}}
Intercell AG was a biotechnology company based in Vienna which focused on the development of modern prophylactic and therapeutic vaccines against infectious diseases. The company merged with Vivalis to form Valneva SE in 2012.{{cite web|url=https://www.fiercebiotech.com/financials/troubled-intercell-throws-towel-signs-off-on-merger-deal-vivalis|publisher=Fierce Biotech|title=Troubled Intercell throws in the towel, signs off on merger deal with Vivalis|first=John|last=Carroll|date=17 December 2012|access-date=27 January 2018}} Intercell was formed in 1998 as a spin-off of the Research Institute of Molecular Pathology (IMP) in Vienna.
{{cite web
|url=http://www.imp.ac.at/about-the-imp/history/
|title=Research Institute of Molecular Pathology (IMP) - About the IMP > History
|publisher=Research Institute of Molecular Pathology
|accessdate=2009-07-25
}} {{Dead link|date=November 2010|bot=H3llBot}}
It employs 400 people in Austria, Scotland and the United States.
History
It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form Valneva.{{Cite news |date=2021-04-29 |title=The Dark Horse of the Vaccine Race May Be This French Biotech |language=en |work=Bloomberg.com |url=https://www.bloomberg.com/news/articles/2021-04-29/a-french-biotech-says-inactivated-vaccines-are-the-way-to-fight-covid-variants |access-date=2023-01-09}}
It has been listed on the Vienna Stock Exchange since February 28, 2005. In 2008, Intercell signaled its intent to acquire Maryland-based Iomai, a developer of needle-free vaccination technology.{{cite web
|url= https://www.reuters.com/article/idUSN1233533220080512
|title= Austrian vaccine maker Intercell buys Iomai
|last= Fox |first=Maggie |last2= Grenon |first2= Andre
|publisher= Reuters |date= 2008-05-12 |accessdate= 2008-08-15
|archiveurl= https://web.archive.org/web/20110620190251/http://www.reuters.com/article/idUSN1233533220080512 |url-status= live
|archivedate = 2011-06-20
| author = Staff | date = 1 June 2008 | title = Intercell to Acquire Iomai for $189M
| periodical = Genetic Engineering & Biotechnology News
| series = News: Inside Industry
| publisher = Mary Ann Liebert, Inc.
| volume = 28 | issue = 11 | page = 14
| url =
| issn = 1935-472X
}}
Intercell cooperates with pharmaceutical companies like Novartis, Merck and Sanofi-Aventis on vaccine production.
The most important projects of Intercell are:
- Vaccine against Japanese encephalitis (approved in Europe, America and Australia)
{{cite web
|url=http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-fda-approval-of-ixiaroR-a-vaccine-against-japanese-encephalitis-a-successf/
|title=Intercell's Japanese Encephalitis Vaccine FDA approval|publisher=Medical News Today
|date=2009-03-31
|accessdate=2009-03-31
}} {{Dead link|date=October 2010|bot=H3llBot}}
{{cite web
|url=http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-european-approval-of-new-vaccine-ixiaroR-to-prevent-japanese-encephalitis/|title=Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe|publisher=Intercell
|date=2009-04-02
|accessdate=2009-04-02
}} {{Dead link|date=October 2010|bot=H3llBot}}
{{cite web
|url=http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/2/back_to/news/article/australian-authorities-tga-first-to-grant-final-product-approval-for-intercells-vaccine-to-preven/|title=Intercell's Japanese Encephalitis Vaccine Australian TGA approval|publisher=Intercell
|date=2009-01-23
|accessdate=2009-01-23
}} {{Dead link|date=October 2010|bot=H3llBot}}
- Therapeutic vaccine against hepatitis C (in clinical phase II)
{{cite web
|url=http://www.fdanews.com/newsletter/article?articleId=97461&issueId=10614
|title=Intercell Hepatitis C Vaccine Meets Primary Endpoints
|publisher=FDA News
|date=2007-08-22
|accessdate=2008-08-15
}}
- Antigen identification program and adjuvant technologies.
- Vaccine Enhancement Patch to improve prevention against pandemic influenza (in collaboration with U.S. Department of Health and Human Services, in clinical phase II)
References
{{Reflist|2}}
External links
- {{Official website|http://www.intercell.com/}}
{{Portal|Companies}}
Category:Companies based in Vienna
Category:Biotechnology companies of Austria
Category:Technology companies established in 1998
Category:Defunct companies of Austria
{{Austria-company-stub}}